Table 3.
Tumor response according to the mRECIST.
Outcome | HAIC with raltitrexed and oxaliplatin post-TACE |
---|---|
DCRa | 75.7%28 |
ORRb | 54.1%20 |
CR | 8.1%3 |
PR | 46.0%17 |
SD | 21.6%8 |
PD | 24.3%9 |
mRECIST: modified Response Evaluation Criteria in Solid Tumors; DCR: disease control rate; ORR, overall response rate; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
DCR was calculated as CR + PR + SD.
ORR was calculated as CR + PR.